OPA1 levels are higher in several tumors including AML, breast, colon, esophageal, lung, ovary, pancreatic, rectum, renal, stomach, testis and uterine cancer, and they positively correlate with resistance to conventional chemotherapeutics [25–29, 37], as predicted given the role of OPA1 as apoptosis inhibitor [24, 30, 38] and angiogenesis initiator [39]. This evidence concerns the gene OPA1 and uterine cancer.